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Summary.-Changes in the structuredness of the cytoplasmic matrix (SCM) of
human lymphocytes induced by PHA, CaBP and EF were studied with the technique
of fluorescence polarization. The study suggests that the SCM test may offer a new
and fast technique for the detection of malignant growth.
WE HAVE reportedrecentlythatnormal
human and chroniclymphocytic leukaemia
(CLL) lymphocytes can be differentiated
on the basis of changes in the structured-
ness of cytoplasmic matrix (SCM) induced
by phytohaemagglutinin (PHA) stimula-
tion (Cercek, Cercek and Garrett, 1974).
By analogy with the effect of PHA
stimulation, we expected other mitogens
and/or antigens to induce changes in the
SCM of lymphocytes which could be used
for the differentiation between various
diseases. In continuation of the previous
study, we have therefore now investigated
the effects of PHA and tumour antigens
(Field and Caspary, 1970), i.e. cancer basic
protein (CaBP) and encephalitogenic fac-
tor (EF), on the cl-hanges in the SCM of
lymphocytes from healthy donors and
patients with malignant and non-malig-
nant disorders. The aim ofthis study was
to find out if changes in the SCM of
lymphocytes evoked by either PHA or
CaBP and/or EF could be used in the
detection of malignancy.
MATERIALS AND METHODS
Separation of lymphocytes-Human lym-
phocytes were prepared from blood collected
in Searle-LH/10 lithium heparin containing
vials. Ten ml samples were transferred into
vials containing 01 g of carbonyl iron
powder Type SF (GAF, Great Britain, Ltd)
26
and rotated at 120 rev/min for 30 min.
Vials were then placed into the incubator at
37°C on a magnet for 10 min. Lymphocytes
in a pure state (>900o) were obtained by the
Ficoll-Triosil gradient separation (Harris and
Ukaejiofo, 1969). The lymphocytes were
washed twice with saline and twice with
TC Medium 199 (Wellcome Ltd) and re-
suspended in TC Medium 199 at the concen-
tration of approximately 5 x 10c cells/ml.
Stimulation of lymphocytes.-Aliquots of
1 ml of lymphocyte suspensions were incu-
bated at 37°C with either 01 ml of a 5 times
diluted reagent grade PHA (Wellcome Ltd),
01 ml of CaBP solution (approximately
50 jug/ml), 01 ml of partly purified CaBP
solution (0-5 ng/ml) or 0 1 ml of EF solution
(approximately 50 jig/ml). CaBP and EF
were donated to us by Dr J. P. Dickinson,
MRC-Demyelinating Diseases Unit, New-
castle General Hospital.
Measurements of SCM.-Changes in the
SCM of lymphocytes were measured with the
technique of fluorescence polarization. The
technique is based on the excitation of the
fluorescein molecules produced by enzymatic
hydrolysis of the non-fluorescing substrate,
fluoresceindiacetate (FDA), in the cytoplasm
with polarized light, and measurement of the
degree of polarization of the emitted fluor-
escence. Aliquots of controls oIr of the
incubated lymphocytes were suspended at
concentrations of 3 x 105 lymphocytes/ml
in 2-5 ,umol/l FDA solution in phosphate
buffered saline. The suspension was rapidly
transferred into a 1 cm cuvette and put intoL. CERCEK, B. CERCEK AND C. I. V. FRANKLIN
the thermostated cuvette holder of the
Perkin-Elmer MPF-2A fluorescence spectro-
photometer fitted with the polarization
accessory. Measurements were made at
27°C. Details ofthe experimental conditions,
procedures and calculations of fluorescence
polarization values, P, were the same as
described in experiments when changes in the
SCM were measured in Chinese Hamster
cells (Cercek, Cercek and Ockey, 1973).
RESULTS
The mean value ofthe SCM oflympho-
cytes from 71 healthy donors is P 0-206
± 0 002 (standard error). The age and
sex distribution of these donors is given
in Table I. The mean value of the SCM
of lymphocytes from 41 donors with
malignant disease is P 0-201 ± 0-0015
(25 females and 16 males aged 16-85
years) and that of lymphocytes of 17
patients with non-malignant disorders is
P 0-188 z 0-002 (10 females and 7
males aged 18-84 years). Details of the
various malignant and non-malignant
cases investigated are given in Tables II
and III.
Lymphocytes from healthy donors
TABLE I.-Healthy Donors
Total number of (lonors testedI with No. of SCM responiders to
PHA Age Sex CaBP Age Sex PHA CaBP RRscM
71* 18-69 22F 41 18-69 12F 70/71 1/41 1-28-1-60
49M 29M (The onie
exception: 0.84)
* Of these 41 wvere tested with CaBP also.
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TABLE II.-Patients with Malignant Diseases
Case
no. Age Sex Diagnosis
SCM decrease
induced by
Treatment before - A-
SCM test PHA CaBP RRSCM
51
61
63
F Carcinoma of breast
F Carcinoma of breast, scirrhous ST2
F Carcinoma of breast: recurrence,
metastases in bones
250 rad
1966 surgery, since
1971 hormones and
chemotherapy
79 F Transitional cell carcinoma of bladder 500 rad
60 M Transitional cell carcinoma of
bladder, ST2
65 F Carcinoma of bladder, ST2
52 F Carcinoma of tongue
61 M Adenocarcinoma of tongue, ST4
60 F Carcinoma of larynx
51 F Squamous cell carcinoma of larynx,
STI
66 M Squamous cell carcinoma of larynx,
ST2 4900 rad
40 F Squamous cell carcinoma of cervix
uteri, ST3
80 F Adenocarcinoma of cervix uteri, ST2
52 F Squamous cell carcinoma of cervix
uteri, ST2
59 F Squamous cell carcinoma of cervix
uteri, ST3
61 F Squamous cell carcinoma of cervix
uteri, ST2B 900 rad
68 F Adenocarcinoma of uterus body, Hysterectomy in
recurrence 1972
30 F Carcinoma of ovary late
56 M Malignant melanoma (recurrence) 430 rad
79 F Malignant melanoma (late) 430 rad
60 M Squamous cell carcinoma of skin:
upper lip
72 F Basal cell carcinoma ofskin: on temple
70 F Skin intra-epidermal carcinoma, ST2
72 M Squamous cell carcinoma of upper 2000 rad to lower lip
(ST2) and lower (STI) lip
67 M Undifferentiated carcinoma of
bronchus (early)
67 M Anaplastic carcinoma of bronchus
(late) 1130 rad
58 M Oat cell carcinoma of bronchus (early)
44 F Glioblastoma of thalamus 465 rad
44 M Astrocytoma, Grade III 495 rad
16 F Osteogenic sarcoma of knee (early) 660 rad
79 M Osteogenic sarcoma or Paget's disease 375 rad
52 F Squamous cell carcinoma in neck,
secondary tumour, primary tumour
unknown 500 rad
68 M Adenocarcinoma of colon, ST2
66 M Squamous cell carcinoma of pharynx
ST3 with metastases in glands 1125 rad
27 F Bone (Ewing's) tumour
57 M Adenocarcinoma of kidney (residual
disease) Surgery
74 F Squamous cell carcinoma of oesophagus
66 F Carcinoma of thyroid with metastases
53 F Reticulum cell sarcoma
64 M Squamous cell carcinoma of larynx
67 M Malignant melanoma 430 rad
" Premalignant " conditions:
34 M Polyposis coli
53 M Hyperkeratosis of skin
0 + 0- 70
0 + 0-71
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Increase
0
0
0
0
0
0
0
+
+
+
+
+
+
0- 75
0- 74
0-86
0- 75
0-71
0-72
0- 73
0-68
0-81
0-81
0-71
0-71
0-72
0- 73
0- 74
0-72
0-68
0-71
0-76
0-69
0-63
0-69
0- 73
0-78
0-69
0-71
0-82
0- 75
0-68
0-76
0-76
0- 73
0- 74
0-67
0-65
0-80
0-89
0-78
0- 90
Increase + 0- 78
+ - 1-08
1
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3
4
5
6
7
8
9
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21
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347
I483 L. CERCEK, B. CERCEK AND C. I. V. FRANKLIN
TABLE III. Patients with Various Non-malignant Disorders
SCM decrease induced bv
Case no. Diagtnosis Age Sex PHA CaBP RRscm
1 Multiple sclerosis 60 F + 0 1 -30
2 Multiple sclerosis 53 M + 0 1-35
3 Infective hepatitis 23 F 0 1 -30
4 Crohn's disease 29 F + 0 1 32
5 Cirrhosis of liver 51 F + 0 1 48
6 Cirrhosis of liver 45 F + 0 1-51
7 Ulcerative colitis 24 M + 0 1 -36
8 Chronic bronchitis 60 M + 0 1 37
9 Chronic bronchitis 61 M + 0 1 -35
10 Chronic bronchitis 67 M + 0 1 -23
11 Rheumatoid arthritis and chronic
bronchitis 57 F + 0 1- 35
12 Rheumatoid arthritis and psoriasis 52 M + 0 1-29
13 Gastric ulcer and benign enlargement
of prostate 84 M + 0 1 36
14 Pregnancy 35 weeks 27 F + 0 1-50
15 Pregnancy 24 weeks 20 F + 0 1 59
16 Pregnancy 32 weeks 18 F + 0 1 50
17 Pregnancy 32 weeks 24 F + 0 1 57
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(70/71 cases) and patients with non-
malignant disorders (17/17 cases)
responded to PHA stimulation with an
immediate decrease in the SCM to 790,( of
the control value followed by a further
slow decrease with time of incubation
(Fig. 1). In contrast, lymphocytes from
all doinors with malignant diseases (Tables
II and IV) did not respond to PHA
stimulation with a decrease in the SCM
for up to 180 min of incubation (Fig. 1).
Lymphocytes from healthv donors
(40/41 cases) and from all patients with
non-malignant disorders did not respond
TABLE IV. SCM Response of Lymphocytes from Different Healthy Donors anad Patients
with Malignant and Non-malignant Disorders to Myelin Protein (EF)
SCM decrease induced by ___
Diagnosis
Cancer of breast
Cancer of breast
Cancer of bladder
Cancer of tongue
Cancer of larynx
S.C.C. Skiii1
Healthy donoi
Healthy donor
Healthy donor
Healthy donor
Healthy donor
Healthy donor
Mutltiple sclerosis
Multiple sclerosis
0
Age
51
61
79
52
60
60
37
21
20
26
43
43
60
53
Sex
F
F
F
F
F
M
M
F
F
F
I
PHA
0
0
0
0
0
0
+
+
RRscru
EF (PEF/PPH\)
+ 0 70
+ 0-71
+-4- 0-73
+ 0-71
+ 0 -070
+ 0 -076
0 1-44
O 1-5
0 1-47
0 1-42
0 1-47
0 1-42
+100
+ 0-99
r 0 0 0
0 0 0
Case no.
1
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3
4
5
6
7
8
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11
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14
300 .1 0 J
( 120 z
0
u
.- 110 0
I6- z
w 100
u
VA
Z80.
0
N70
Wu.
_0.
20 40 60 80 160 12o 140 160 180 200 220 370
INCUBATION TIME, (min.)
Fic.. 3.-Effect of EF oIn the SCAI of human lymphocytes: 0 6 healthy donors; 0 6
donors with malignant disease.
p- e% r
I A
- .F %
349L. CERCEK, B. CERCEK AND C. I. V. FRANKLIN
to CaBP stimulation for up to 180 min
of incubation (Fig. 2 and Tables I and
III). Similarly, the lymphocytes from
healthy donors (6/6 cases) did not respond
to EF stimulation (Fig. 3, Table IV).
However, lymphocytes from 2 donors
with a demyelinating disease (multiple
sclerosis) responded to EF stimulation
with a decrease in the SCM (Table IV).
Lymphocytes from donors with malig-
nant diseases (41/41 cases) responded to
CaBP and to EF (6/6 cases) stimulation
with an immediate decrease in the SCM
to 76% of the control value followed by a
further slow decrease with time of incuba-
tion (Fig. 2, 3). In 2 cases of pre-
malignant conditions, i.e. polyposis coli
(familial cancer) and hyperkeratosis ofthe
skin, the lymphocytes responded to CaBP
stimulation with a decrease in the SCM
to 910% of the control value.
To express the response ofthe lympho-
cytes to CaBP and PHA stimulation as a
single parameter we have calculated the
" SCM Response Ratio " (RRScM). The
RRSCM value is the ratio of the degree of
fluorescence polarization obtained after
CaBP stimulation, PcaBP, over that after
PHA stimulation, PPHA, both measured
at comparable times after 30 to 100 min
ofincubation:
RRscM PCaBP/PPHA
A histogram of RRSCM values for
lymphocytes from healthy donors, donors
with malignant diseases and non-malig-
nant disorders is shown in Fig. 4. It can
be seen that the lymphocytes from
patients with malignant diseases can be
differentiated easily from the lymphocytes
of other donors on the basis of the
RRscmr parameter.
DISCUSSION
The physical phenomenon of changes
in the SCM appears to be a sensitive
monitor of the ability of lymphocytes to
respond to mitogenic and/or antigenic
stimuli (Cercek et al., 1974). The sum-
mary of the results in Fig. 1, 2 and 3
shows that lymphocytes fronm donors with
various malignant diseases (Table II) can
be differentiated from lymphocytes of
healthy donors and from donors with
various non-malignant disorders (Table
III) which in other tests for the diagnosis
ofhuman cancer gave false positive results
(Lawrence and Neville, 1972; Tee, 1973;
Field, Caspary and Smith, 1973). The
lymphocytes from cancer patients respond
to stimulation by CaBP (or EF) but not to
that by PHA, whereas the lymphocytes
from healthy donors and patients with
non-malignant disorders respond to stimu-
lation by PHA but not to that by CaBP
(or EF, except 2 cases of multiple
sclerosis).
A clear-cut separation ofthe malignant
and non-malignant cases is also obtained
by the frequency distribution of the
RRSCM values (Fig. 4), which measure the
magnitude of the response both to PHA
and CaBP stimulation and thus could
become diagnostically useful. In the
progression from the normal to " pre-
malignant " to malignant state the RRscM
value appears to decrease (progressively?)
from values greater than 1 to smaller than
1. For example, a case of hyperkeratosis
of the skin whose lymphocytes responded
to PHA and CaBP stimulation with a
16% and 900 decrease in the SCM,
respectively, gave a low RRSCM value of
1P08, but fully developed cancers of the
skin gave RRSCM values from 0 63 to
0 69 (Table II).
Similarly, in a case of the familial
con0lition, polyposis coli, the lymphocytes
responded to CaBP stimulation with a
small (90%) decrease in the SCM; however,
on stimulation with PHA the response
was a 1700 increase, similar to that
observed in CLL lymphocytes (Cercek
et al., 1974). The RRSCM value in this
case was 0-78.
Unlike with the macrophage migration
inhibition test (Field et al., 1973), the
lymphocytes from 2 cases of multiple
sclerosis responded to PHA and CaBP in
the same way as those from healthy
donors (Table III) but responded to EF
350351 BIOPHYSICAL DIFFERENTIATION BETWEEN LYMPHOCYTES
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FIG. 4. Frequency distribution of the SCM Response Ratio (RRscM) of lymphocytes from healthy
donors, patients with malignant diseases and various other disorders: [- malignant diseases;
. healthy donors; 1. multiple sclerosis; 2. infective hepatitis; 3. Crohn's disease; 4. cirrhosis of
liver; 5. pregnancy (24-35 weeks); 6. ulcerative colitis; 7. chronic bronchitis; 8. rheumatoid
arthritis combined with chronic bronchitis and psoriasis; 9. peptic ulcer and benign enlargement
of prostate; 10. hyperkeratosis of the skin; 11. polyposis coli; 12. normal donor (the exception).
with a decrease in the SCM similar to that
observed in cancer patients. This obser-
vation suggests the possible usefulness of
the SCM test in differentiating demyeli-
nating conditions from malignancies of
the central nervous system.
Among the 71 healthy donors we
found only one (a 59-year old male) whose
lymphocytes responded to PHA and CaBP
stimulation in the same way as lympho-
cytes from donors with cancer. The
RRSCM value was 0-91 and 8 weeks later
it was 0-84. Clinical examination did not
reveal any obvious sign of malignant
process. Further studies on the correla-
tion between the values of RRSCM and
early stages of malignant growth should
help to decide if such exceptions are
"false positives" or cases of early
malignant growth which elude the macro-
scopic methods of the routine clinical
examinations.
From the magnitude, mode and time
dependence of the response it appears
that the same type and size of cell
population (? T cell) is involved in the
change of SCM induced by PHA and
CaBP. Furthermore, EF may carry 2
types of determinants, one recognized by
the receptors oflymphocytes from patients
with cancer, the other by lymphocytes
from patients with multiple sclerosis.
The present study suggests that the
SCM test may offer a new and fast
technique for the detection of a malignant
growth. A long-term study on a larger
number of cases is needed to explore the
applicability of the SCM test and of the
RRScM parameter for diagnostic and
prognostic purposes.
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